4-Methylideneisoxazolidin-5-ones - A new class of α-methylidene- γ-lactones with high cytostatic activity

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 5, 2006, Pages 1430-1433

  Janecki, Tomasz ^a   Wa̧sek, Tomasz ^a   Rózalski, Marek ^b   Krajewska, Urszula ^b   Studzian, Kazimierz ^b   Janecka, Anna ^b  

^a LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Methylidene lactones; Cytostatic activity; Horner Wadsworth Emmons olefination; Isoxazolidin 5 ones

Indexed keywords

4 DIETHOXYPHOSPHORYLISOXAZOLIDIN 5 ONE DERIVATIVE; 4 METHYLIDENEISOXAZOLIDIN 5 ONE DERIVATIVE; ALKENE DERIVATIVE; ALPHA METHYLIDENE GAMMA LACTONE DERIVATIVE; ETHYL 2 DIETHOXYPHOSPHORYL 2 ALKENOATE DERIVATIVE; FORMALDEHYDE; GAMMA LACTONE DERIVATIVE; HYDROXYLAMINE; N METHYLHYDROXYLAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOSTASIS; DRUG CLASSIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HORNER WADSWORTH EMMONS REACTION; HUMAN; HUMAN CELL; IC 50; LACTONIZATION; LEUKEMIA CELL LINE; NONHUMAN;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; INHIBITORY CONCENTRATION 50; LACTONES; LEUKEMIA; MOLECULAR STRUCTURE; OXAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 31444446499     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.11.032     Document Type: Article

References (25)

1. H.M.R. Hoffmann, and J. Rabe Angew. Chem., Int. Ed. Engl. 24 1985 94
2. P.G. Baraldi, M.C. Nunez, M.A. Tabrizi, E. De Clercq, J. Balzarini, J. Bermejo, F. Estevez, and R. Romagnoli J. Med. Chem. 47 2004 2877
3. J. Heilmann, M.R. Wasescha, and T.J. Schmidt Bioorg. Med. Chem. 9 2001 2189
4. B.P. Patel, T.G. Waddell, and R.M. Pagni Fitoterapia 72 2001 511
5. J.H. Cardellina, and R.E. Moore Tetrahedron Lett. 22 1979 2007
6. T. Naito, Y. Honda, O. Miyata, and I. Ninomiya Chem. Pharm. Bull. 41 1993 217
7. C. Belaud, C. Roussakis, Y. Letourneux, N. El Alami, and J. Villieras Synth. Commun. 15 1985 1233
8. T. Janecki, E. Błaszczyk, K. Studzian, A. Janecka, U. Krajewska, and M. Różalski J. Med. Chem. 48 2005 3516
9. T. Janecki, E. Błaszczyk, K. Studzian, M. Różalski, U. Krajewska, and A. Janecka J. Med. Chem. 45 2002 1142
10. T. Janecki, A. Albrecht, E. Warzycha, K. Studzian, A. Janecka, U. Krajewska, and M. Różalski Chem. Biodiv. 2 2005 1256
11. G. Shaw J. Chem. Soc. 1951 1017
12. A.P. Piechowski, G.R. Bird, D.L. Morel, and E.L. Stogryn J. Phys. Chem. 88 1984 934
13. T. Janecki, A. Kuś, H. Krawczyk, and E. Błaszczyk Synlett 2000 611
14. H. Krawczyk, and Ł. Albrecht Synthesis 2005 2887
15. 4 and concentrated in vacuo.
16. M.B. Smith, and J. March March's Advanced Organic Chemistry 2001 John Wiley & Sons New York 977
17. T. Janecki, and T. Wa̧sek Tetrahedron 60 2004 1049
18. R.S. Macomber A Complete Introduction to Modern NMR Spectroscopy 1998 John Wiley & Sons New York 76
19. (b) Verkade, J. G., Quin, L. D., Eds.; Phosphorus-31 NMR Spectroscopy in Stereochemical Analysis; VCH Publishers, Inc.: Deerfield Beach, FL, 1987; pp 391-424.
20. 2: C, 70.92; H, 6.45; N, 6.89. Found: C, 70.73; H, 6.48; N, 6.62.
21. 15b.
22. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Cancer Res. 47 1987 936
23. 50 values (a concentration of the tested compounds required to reduce a fraction of the surviving cells to 50% of that observed in the control cells) were calculated from dose-response curves and used as an index of cellular sensitivity to a given treatment. All the data are expressed as means ± SD.
24. Canetta, R.; Goodlow, J.; Smaldone, L.; et al. In Carboplatin (JM-8): Current Perspectives and Future Directions, Bunn P. A., Canetta R., Ozols R. F., et al., Eds.; W. B. Saunders: Philadelphia, PA, 1990; pp 19-38.
25. S.M. Kupchan, M.A. Eakin, and A.M. Thomas J. Med. Chem. 14 1971 1147